Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Stoke Therapeutics, Inc.STOK · Entity 1723 | Director · 10% owner | September 10, 2019 | September 13, 2019 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Stoke Therapeutics, Inc.
Report date September 10, 2019 · Filed September 13, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Director Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $28.80 · Expires 2029-09-09 | Direct | 29,555 |
Reported balance
After 2019-09-10 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2019-09-10 · Grant · Acquired 29,555 · Balance 29,555 F1: This option shall vest (i) 1/12th of the total shares on June 21, 2019; and then (ii) quarterly as to 1/12th of the total shares, commencing the first quarter following June 21, 2019, subject to Reporting Person's continued service through each vesting date. F2: Under the Reporting Person's arrangement with Apple Tree Life Sciences, Inc. (the "Manager"), the Reporting Person holds the option for the benefit of Apple Tree Partners IV, L.P. (the "Fund"). The Reporting Person is obligated to turn over to the Manager any net cash or stock received upon exercise of the option, which will offset advisory fees owed by the Fund to the Manager. The Reporting Person therefore disclaims beneficial ownership of the option and underlying common stock. |
Filing footnotes · ownership attribution and instrument terms
F1: This option shall vest (i) 1/12th of the total shares on June 21, 2019; and then (ii) quarterly as to 1/12th of the total shares, commencing the first quarter following June 21, 2019, subject to Reporting Person's continued service through each vesting date.
F2: Under the Reporting Person's arrangement with Apple Tree Life Sciences, Inc. (the "Manager"), the Reporting Person holds the option for the benefit of Apple Tree Partners IV, L.P. (the "Fund"). The Reporting Person is obligated to turn over to the Manager any net cash or stock received upon exercise of the option, which will offset advisory fees owed by the Fund to the Manager. The Reporting Person therefore disclaims beneficial ownership of the option and underlying common stock.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| September 10, 2019 Filed Sep 13, 2019 00:10 UTC | Stoke Therapeutics, Inc. STOK · Entity 1723 | GrantDirector Stock Option (Right to Buy) · Derivative | 29,555 | $0.00 Strike: $28.80 | $0.00 |
DisclosureSEC source: 0001567619-19-018224 · doc1.xml · derivative · entry 1 Hall Samuel W. · CIK 0001780090 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,555 Underlying: Common Stock · 29,555 shares Expires 2029-09-09 F1 · derivative.exercise_date: This option shall vest (i) 1/12th of the total shares on June 21, 2019; and then (ii) quarterly as to 1/12th of the total shares, commencing the first quarter following June 21, 2019, subject to Reporting Person's continued service through each vesting date. F2 · ownership.direct: Under the Reporting Person's arrangement with Apple Tree Life Sciences, Inc. (the "Manager"), the Reporting Person holds the option for the benefit of Apple Tree Partners IV, L.P. (the "Fund"). The Reporting Person is obligated to turn over to the Manager any net cash or stock received upon exercise of the option, which will offset advisory fees owed by the Fund to the Manager. The Reporting Person therefore disclaims beneficial ownership of the option and underlying common stock. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.